Riltozinameran is a component of a bivalent COVID-19 mRNA vaccine encoding the viral spike protein of Omicron variant lineage BA.1. The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021.
- Mechanism
- Curator reviewed · 1 reference
Riltozinameran is a nucleoside-modified mRNA encapsulated in lipid nanoparticles that facilitate the delivery of the mRNA into human cells. Once inside the host cells, the mRNA is translated by host machinery to produce a modified SARS-CoV-2 spike (S) protein - specifically the S protein of the Omicron BA.1 variant lineage - which is subsequently recognized by the host immune system. Both neutralizing antibody and cellular immune responses are elicited in response to the vaccine, which helps protect against SARS-CoV-2 infection.
- Primary indication
- Riltozinameran, in combination with tozinameran (Comirnaty Original / Omicron BA.1), is indicated in patients ≥12 years of age as a booster dose for active immunization against COVID-19 caused by SARS-CoV-2.Curator reviewed · 1 structured indication
- First approval
- Canada, 2022
- Code names
- BNT162B2_B.1.1.529
Resolves to
What you can answer from here — as of March 11, 2023
Which other approved drugs treat the same conditions as Riltozinameran, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account